Fujitsu Ltd. and Mitsubishi Chemical Corp. plan to combine their respective strengths to generate business in the medical field through a joint project focusing on genomic drug research, the two companies announced Thursday.
Tied to the recent decoding of the human genome, such drugs will be highly specific in the genomes, genes and proteins that they attack and have the potential to revolutionize medicine.
The project will see Fujitsu working on developing specialized high performance computer systems for analyzing vast amounts of bio-information, the companies said in a statement. The machines will be supplied to Mitsubishi Chemical which will use them, along with its existing knowledge and intellectual property, to develop genomic drugs.
The two companies said they have already formed a team to map out a research strategy for the venture and expect to develop a business plan in the coming months. Together they hope to form new businesses related to the genomic drugs research field.
Fujitsu, in Tokyo, can be contacted at +81-3-3216-3211 or online at http://www.fujitsu.co.jp/. Mitsubishi Chemical can be contacted at http://www.m-kagaku.co.jp.